Cargando…
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in a...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875597/ https://www.ncbi.nlm.nih.gov/pubmed/27209210 http://dx.doi.org/10.1186/s13048-016-0238-7 |
_version_ | 1782433118107467776 |
---|---|
author | Mignogna, Chiara Staropoli, Nicoletta Botta, Cirino De Marco, Carmela Rizzuto, Antonia Morelli, Michele Di Cello, Annalisa Franco, Renato Camastra, Caterina Presta, Ivan Malara, Natalia Salvino, Angela Tassone, Pierfrancesco Tagliaferri, Pierosandro Barni, Tullio Donato, Giuseppe Di Vito, Anna |
author_facet | Mignogna, Chiara Staropoli, Nicoletta Botta, Cirino De Marco, Carmela Rizzuto, Antonia Morelli, Michele Di Cello, Annalisa Franco, Renato Camastra, Caterina Presta, Ivan Malara, Natalia Salvino, Angela Tassone, Pierfrancesco Tagliaferri, Pierosandro Barni, Tullio Donato, Giuseppe Di Vito, Anna |
author_sort | Mignogna, Chiara |
collection | PubMed |
description | High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10–0 % of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months). On these bases, a careful selection of patients who could benefit from chemotherapy is recommended to avoid unnecessary side effects and for a better disease outcome. In this retrospective study, an immunohistochemical evaluation of Aurora Kinase A (AURKA) was performed on 41 cases of HGSOC according to platinum-status. Taking into account the number and intensity of AURKA positive cells we built a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant patients (p < 0.001). Furthermore, we observed that AURKA overexpression correlates to worse overall survival (p = 0.001; HR 0.14). We here suggest AURKA as new effective tool to predict the biological behavior of HGSOC. Particularly, our results indicate that AURKA has a role both as predictor of platinum-resistance and as prognostic factor, that deserves further investigation in prospective clinical trials. Indeed, in the era of personalized medicine, AURKA could assist the clinicians in selecting the best treatment and represent, at the same time, a promising new therapeutic target in EOC treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13048-016-0238-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4875597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48755972016-05-22 Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients Mignogna, Chiara Staropoli, Nicoletta Botta, Cirino De Marco, Carmela Rizzuto, Antonia Morelli, Michele Di Cello, Annalisa Franco, Renato Camastra, Caterina Presta, Ivan Malara, Natalia Salvino, Angela Tassone, Pierfrancesco Tagliaferri, Pierosandro Barni, Tullio Donato, Giuseppe Di Vito, Anna J Ovarian Res Brief Communication High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10–0 % of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months). On these bases, a careful selection of patients who could benefit from chemotherapy is recommended to avoid unnecessary side effects and for a better disease outcome. In this retrospective study, an immunohistochemical evaluation of Aurora Kinase A (AURKA) was performed on 41 cases of HGSOC according to platinum-status. Taking into account the number and intensity of AURKA positive cells we built a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant patients (p < 0.001). Furthermore, we observed that AURKA overexpression correlates to worse overall survival (p = 0.001; HR 0.14). We here suggest AURKA as new effective tool to predict the biological behavior of HGSOC. Particularly, our results indicate that AURKA has a role both as predictor of platinum-resistance and as prognostic factor, that deserves further investigation in prospective clinical trials. Indeed, in the era of personalized medicine, AURKA could assist the clinicians in selecting the best treatment and represent, at the same time, a promising new therapeutic target in EOC treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13048-016-0238-7) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-21 /pmc/articles/PMC4875597/ /pubmed/27209210 http://dx.doi.org/10.1186/s13048-016-0238-7 Text en © Mignogna et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Brief Communication Mignogna, Chiara Staropoli, Nicoletta Botta, Cirino De Marco, Carmela Rizzuto, Antonia Morelli, Michele Di Cello, Annalisa Franco, Renato Camastra, Caterina Presta, Ivan Malara, Natalia Salvino, Angela Tassone, Pierfrancesco Tagliaferri, Pierosandro Barni, Tullio Donato, Giuseppe Di Vito, Anna Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients |
title | Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients |
title_full | Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients |
title_fullStr | Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients |
title_full_unstemmed | Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients |
title_short | Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients |
title_sort | aurora kinase a expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875597/ https://www.ncbi.nlm.nih.gov/pubmed/27209210 http://dx.doi.org/10.1186/s13048-016-0238-7 |
work_keys_str_mv | AT mignognachiara aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT staropolinicoletta aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT bottacirino aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT demarcocarmela aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT rizzutoantonia aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT morellimichele aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT dicelloannalisa aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT francorenato aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT camastracaterina aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT prestaivan aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT malaranatalia aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT salvinoangela aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT tassonepierfrancesco aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT tagliaferripierosandro aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT barnitullio aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT donatogiuseppe aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients AT divitoanna aurorakinaseaexpressionpredictsplatinumresistanceandadverseoutcomeinhighgradeserousovariancarcinomapatients |